
RTX's Collins Aerospace expands aircraft electrification capabilities in Europe
PARIS, June 9, 2025 /PRNewswire/ -- Collins Aerospace, an RTX (NYSE: RTX) business, expanded its aircraft electrification capabilities with the introduction of a new engineering center of excellence in Wolverhampton, UK, and a new electric thrust reverser actuation systems (elecTRAS™) production line in Colomiers, France. The Wolverhampton center focuses on developing next-generation electric thrust reverser actuation systems for commercial aircraft, featuring state-of-the-art design and test capabilities, and the Colomiers facility will handle the final assembly of these advanced electric systems, enhancing production efficiency and capacity.
By switching from traditional hydraulic-powered thrust reverser actuation systems to elecTRAS, Collins can design nacelle systems that are easier for customers to install and maintain, while also reducing aircraft system weight by 15-20%. This improves fuel efficiency and operational performance. Collins currently supplies the elecTRAS on the Airbus A350 family. As part of an aircraft's nacelle system, thrust reversers redirect thrust from the plane's engines to help it slow down upon landing.
The final assembly of the system in Colomiers will increase Collins' nacelle integration capacity and enhance customer proximity. Collectively, these efforts will strengthen Collins' aircraft electrification capabilities to support its global customer base.
"With decades of experience in nacelles, thrust reversers, and aircraft electrification, Collins' elecTRAS center of excellence and production line will bring together expertise from across the company to deliver new, innovative solutions for our customers and future platforms," said Ajay Mahajan, president of Aerostructures at Collins Aerospace. "Building on in-service learning and experience, our dedicated investment to enable aircraft electrification technologies for the next-generation nacelle and elecTRAS will make future aircraft easier to maintain and operationally efficient."
The new Wolverhampton site will serve as the engineering design center for elecTRAS, collaborating closely with Collins' Aerostructures headquarters in Chula Vista, California and other global engineering centers. It will also collaborate with Collins' electronic controls and motor systems center of excellence in Solihull, UK.
With more than 600 A350XWB aircraft in service at the end of 2024 and continued production into the next decade, Collins' latest generation elecTRAS has accrued approximately 11 million flight hours and 1.8 million flight cycles of in-service operational experience.
About Collins AerospaceCollins Aerospace, an RTX business, is a leader in integrated and intelligent solutions for the global aerospace and defense industry. Our 80,000 employees are dedicated to delivering future-focused technologies to advance sustainable and connected aviation, passenger safety and comfort, mission success, space exploration, and more
About RTXRTX is the world's largest aerospace and defense company. With more than 185,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. Through industry-leading businesses – Collins Aerospace, Pratt & Whitney, and Raytheon – we are advancing aviation, engineering integrated defense systems for operational success, and developing next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2024 sales of more than $80 billion, is headquartered in Arlington, Virginia.
For questions or to schedule an interview, please contact corporatepr@rtx.com
View original content:https://www.prnewswire.com/news-releases/rtxs-collins-aerospace-expands-aircraft-electrification-capabilities-in-europe-302476348.html
SOURCE RTX

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
23 minutes ago
- Business Wire
Earnings Teleconference Moves to Earlier Time on July 29
--(BUSINESS WIRE)--As previously announced, UnitedHealth Group will release its second quarter 2025 financial results on Tuesday, July 29, 2025, before the market opens. The start time for the teleconference has moved to 8:00 a.m. ET, 45 minutes earlier than previously announced, to allow more time for discussion of results with analysts and investors. This call will be webcast on the Investor Relations page of the company's website ( The replay will be available through August 12 on the website. UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn.


Business Wire
23 minutes ago
- Business Wire
SYNOVUS FINANCIAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Synovus Financial Corp.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Synovus Financial Corp. (NYSE: SNV) and Pinnacle Financial Partners (NasdaqGS: PNFP). Upon completion of the proposed transaction, Synovus shareholders will own approximately 48.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Synovus shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
38 minutes ago
- Yahoo
Why Elanco (ELAN) Stock Is Trading Up Today
What Happened? Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia. The treatment, Zenrelia, was approved as a once-daily oral medication to treat itching and atopic dermatitis in dogs. This decision by the European Commission represented a significant milestone for Elanco, allowing it to expand its presence in the European canine dermatology market. The company stated the product was expected to be available by the end of the third quarter of 2025. The news followed a recent analyst upgrade from UBS Group, which raised its price target on Elanco shares to $18.00 from $17.00, reiterating a 'buy' rating on the stock. After the initial pop the shares cooled down to $14.85, up 1.1% from previous close. Is now the time to buy Elanco? Access our full analysis report here, it's free. What Is The Market Telling Us Elanco's shares are quite volatile and have had 16 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 21.2% on the news that the company reported decent first quarter 2025 results which beat analysts' EPS expectations and included constant currency revenue outperformance. Organic sales were up 4%, thanks to strong demand in cattle health and good traction from new pet meds like Credelio Quattro. Even though sales were flat, operating margins improved, a sign they're managing prices and costs pretty well. On the other hand, its full-year EBITDA guidance missed. Overall, we think this was a decent quarter with some key metrics above expectations. Elanco is up 23.2% since the beginning of the year, and at $14.85 per share, it is trading close to its 52-week high of $15.47 from August 2024. Investors who bought $1,000 worth of Elanco's shares 5 years ago would now be looking at an investment worth $696.95. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data